

Interaction Report

Report ID:

Date Produced:

06 May 2025

Antiretroviral Treatment

Co-medications

Efavirenz (EFV)

Salmeterol

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown.

For full details of all interactions, see www.hiv-druginteractions.org.

Description of the interactions

Potential clinically significant interaction - likely to require additional monitoring, alteration of drug dosage or timing of administration (AMBER)

Efavirenz (EFV) + Salmeterol

Coadministration has not been studied. Salmeterol is metabolized by CYP3A4. Efavirenz is an inducer of CYP3A4 and could potentially decrease salmeterol concentrations. The clinical relevance is unknown.